Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

HIV Infection

Free Subscription Articles published in Lancet Infect Dis Retrieve available abstracts of 106 articles: HTML format

Single Articles

November 2023
1. DUARTE-NETO AN, Goncalves AM, Eliodoro RHA, Martins WD, et al
   Main autopsy findings of visceral involvement by fatal mpox in patients with AIDS: necrotising nodular pneumonia, nodular ulcerative colitis, and diffuse vasculopathy.
   Lancet Infect Dis. 2023;23:1218-1222.
   PubMed    
   
   
   
2. TAHA AM, Rodriguez-Morales AJ, Sah R
   Mpox breakthrough infections: concerns and actions.
   Lancet Infect Dis. 2023;23:1216-1218.
   PubMed    
   
   
   October 2023
3. OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
   Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
   Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
   PubMed     Abstract available
   
   
   
4. TRKOLA A, Moore PL
   Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines.
   Lancet Infect Dis. 2023 Oct 23:S1473-3099(23)00481.
   PubMed     Abstract available
   
   
   September 2023
5. PINNETTI C, Cimini E, Mazzotta V, Matusali G, et al
   Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
   Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00482.
   PubMed     Abstract available
   
   
   
6. URIU K, Ito J, Kosugi Y, Tanaka YL, et al
   Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
   Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
   PubMed    
   
   
   
7. KAKU Y, Kosugi Y, Uriu K, Ito J, et al
   Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
   Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
   PubMed    
   
   
   
8. SHERWOOD-MARTIN H
   Aging with HIV in sub-Saharan Africa.
   Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00570.
   PubMed    
   
   
   
9. ZHANG XS, Mandal S, Mohammed H, Turner C, et al
   Transmission dynamics and effect of control measures on the 2022 outbreak of mpox among gay, bisexual, and other men who have sex with men in England: a mathematical modelling study.
   Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00451.
   PubMed     Abstract available
   
   
   
10. LITVINJENKO S, Magwood O, Wu S, Wei X, et al
    Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews.
    Lancet Infect Dis. 2023 Sep 8:S1473-3099(23)00372.
    PubMed     Abstract available
    
    
    
11. HAZRA A, Zucker J, Bell E, Flores J, et al
    Mpox in people with past infection or a complete vaccination course: a global case series.
    Lancet Infect Dis. 2023 Sep 4:S1473-3099(23)00492.
    PubMed     Abstract available
    
    
    
12. JESUDASON T
    Global progress reported for AIDS.
    Lancet Infect Dis. 2023;23:e342.
    PubMed    
    
    
    
13. THE LANCET INFECTIOUS DISEASES
    Negligible role of suppressed HIV in sexual transmission.
    Lancet Infect Dis. 2023;23:983.
    PubMed    
    
    
    August 2023
14. DAS R, Blazquez-Gamero D, Bernstein DI, Gantt S, et al
    Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2023 Aug 31:S1473-3099(23)00343.
    PubMed     Abstract available
    
    
    
15. FAUST L, Naidoo P, Caceres-Cardenas G, Ugarte-Gil C, et al
    Improving measurement of tuberculosis care cascades to enhance people-centred care.
    Lancet Infect Dis. 2023 Aug 28:S1473-3099(23)00375.
    PubMed     Abstract available
    
    
    
16. OGOINA D, Dalhat MM, Denue BA, Okowa M, et al
    Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study.
    Lancet Infect Dis. 2023 Aug 22:S1473-3099(23)00427.
    PubMed     Abstract available
    
    
    
17. ASHLEY-NORMAN P
    A holistic approach to HIV management.
    Lancet Infect Dis. 2023 Aug 16:S1473-3099(23)00544.
    PubMed    
    
    
    
18. GRANT R, Benamouzig D, Catton H, Cheng VC, et al
    COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
    Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
    PubMed    
    
    
    
19. HERRERA K, Lyang J, Holly T, Faherty EA, et al
    Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpox.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00483.
    PubMed    
    
    
    
20. OUK V, Pham CD, Wi T, van Hal SJ, et al
    The Enhanced Gonococcal Surveillance Programme, Cambodia.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00479.
    PubMed    
    
    
    July 2023
21. VENKATESAN P
    Statin use in people living with HIV.
    Lancet Infect Dis. 2023;23:789.
    PubMed    
    
    
    June 2023
22. KOREN MA, Lin L, Eckels KH, De La Barrera R, et al
    Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00192.
    PubMed     Abstract available
    
    
    
23. TEICHER A
    Super-spreaders: a historical review.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00183.
    PubMed     Abstract available
    
    
    
24. DUBE K, Morton T, Fox L, Dee L, et al
    A partner protection package for HIV cure-related trials involving analytical treatment interruptions.
    Lancet Infect Dis. 2023 Jun 6:S1473-3099(23)00267.
    PubMed     Abstract available
    
    
    
25. WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
    How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
    PubMed     Abstract available
    
    
    
26. CHEN MY, Williamson DA
    Sexually acquired enteric infections among men who have sex with men.
    Lancet Infect Dis. 2023;23:644-645.
    PubMed    
    
    
    May 2023
27. GARCIA-PRATS AJ, Hoddinott G, Howell P, Hughes J, et al
    Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis.
    Lancet Infect Dis. 2023 May 25:S1473-3099(23)00349.
    PubMed    
    
    
    
28. YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
    PubMed    
    
    
    
29. IZU A, Nunes MC, Solomon F, Baillie V, et al
    All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
    PubMed     Abstract available
    
    
    April 2023
30. KIMATHI D, Juan-Giner A, Orindi B, Grantz KH, et al
    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00114.
    PubMed     Abstract available
    
    
    
31. VENKATESAN P
    HIV vaccine trial failure.
    Lancet Infect Dis. 2023;23:410.
    PubMed    
    
    
    March 2023
32. CROSS GB, Sari IP, Kityo C, Lu Q, et al
    Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Lancet Infect Dis. 2023 Mar 23:S1473-3099(23)00067.
    PubMed     Abstract available
    
    
    
33. BERTRAN M, Andrews N, Davison C, Dugbazah B, et al
    Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00057.
    PubMed     Abstract available
    
    
    
34. CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
    Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
    Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
    PubMed     Abstract available
    
    
    
35. BAGCCHI S
    Poland provides HIV care to Ukrainian refugees.
    Lancet Infect Dis. 2023;23:287.
    PubMed    
    
    
    
36. MUSHTAQ A, Kazi F
    Lenacapavir: a new treatment of resistant HIV-1 infections.
    Lancet Infect Dis. 2023;23:286.
    PubMed    
    
    
    February 2023
37. STAFFORD A, Rimmer S, Gilchrist M, Sun K, et al
    Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection.
    Lancet Infect Dis. 2023 Feb 8:S1473-3099(23)00044.
    PubMed     Abstract available
    
    
    
38. YUE C, Song W, Wang L, Jian F, et al
    ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
    Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
    PubMed    
    
    
    January 2023
39. URIU K, Ito J, Zahradnik J, Fujita S, et al
    Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
    Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
    PubMed    
    
    
    December 2022
40. FINK DL, Callaby H, Luintel A, Beynon W, et al
    Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.
    Lancet Infect Dis. 2022 Dec 22:S1473-3099(22)00806.
    PubMed     Abstract available
    
    
    
41. LAKOH S, Kamudumuli PS, Penney ROS, Haumba SM, et al
    Diagnostic capacity for invasive fungal infections in advanced HIV disease in Africa: a continent-wide survey.
    Lancet Infect Dis. 2022 Dec 21:S1473-3099(22)00656.
    PubMed     Abstract available
    
    
    
42. SUNER C, Ubals M, Tarin-Vicente EJ, Mendoza A, et al
    Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain.
    Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00794.
    PubMed     Abstract available
    
    
    
43. SCHWARZ M, Schwarz C, Mossig E, Lampichler K, et al
    Isolated peritoneal involvement as a primary manifestation of cystic echinococcosis.
    Lancet Infect Dis. 2022;22:1769.
    PubMed    
    
    
    November 2022
44. MOGENSEN TH, Skouboe MK, Molle I
    Successful use of interferon alfa-2a for persistent parvovirus B19 infection.
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00685.
    PubMed     Abstract available
    
    
    
45. CHANG CH, Hung JH, Hsu SM
    Ocular toxoplasmosis in a patient with acquired immunodeficiency syndrome.
    Lancet Infect Dis. 2022 Nov 14. pii: S1473-3099(22)00737.
    PubMed    
    
    
    
46. EKE AC, Gebreyohannes RD, Powell AM
    Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women.
    Lancet Infect Dis. 2022 Nov 11. pii: S1473-3099(22)00687.
    PubMed     Abstract available
    
    
    
47. AGRATI C, Cossarizza A, Mazzotta V, Grassi G, et al
    Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study.
    Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00662.
    PubMed     Abstract available
    
    
    
48. SHARLAND M, Cappello B, Ombajo LA, Bazira J, et al
    The WHO AWaRe Antibiotic Book: providing guidance on optimal use and informing policy.
    Lancet Infect Dis. 2022;22:1528-1530.
    PubMed    
    
    
    October 2022
49. DORON S, Gandhi M
    New boosters are here! Who should receive them and when?
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
    PubMed    
    
    
    
50. MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
    Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
    PubMed     Abstract available
    
    
    
51. KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
    Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
    PubMed     Abstract available
    
    
    
52. ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
    Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
    Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
    PubMed     Abstract available
    
    
    
53. BAGCCHI S
    Global alliance to tackle HIV in children.
    Lancet Infect Dis. 2022;22:1426.
    PubMed    
    
    
    September 2022
54. PALICH R, Burrel S, Monsel G, Nouchi A, et al
    Viral loads in clinical samples of men with monkeypox virus infection: a French case series.
    Lancet Infect Dis. 2022 Sep 29. pii: S1473-3099(22)00586.
    PubMed     Abstract available
    
    
    
55. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    PubMed    
    
    
    
56. ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
    Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
    PubMed    
    
    
    
57. ONYEGBU C
    The persistence of HIV stigma in Kenya.
    Lancet Infect Dis. 2022;22:1292.
    PubMed    
    
    
    
58. BURKI T
    Involuntary sterilisation and HIV.
    Lancet Infect Dis. 2022;22:1284.
    PubMed    
    
    
    
59. MARX FM, Hesseling AC, Martinson N, Theron G, et al
    National survey in South Africa reveals high tuberculosis prevalence among previously treated people.
    Lancet Infect Dis. 2022;22:1273.
    PubMed    
    
    
    
60. LAPA D, Carletti F, Mazzotta V, Matusali G, et al
    Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding.
    Lancet Infect Dis. 2022;22:1267-1269.
    PubMed    
    
    
    August 2022
61. RAJASINGHAM R, Govender NP, Jordan A, Loyse A, et al
    The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.
    Lancet Infect Dis. 2022 Aug 29. pii: S1473-3099(22)00499.
    PubMed     Abstract available
    
    
    
62. ZHAO FH, Wu T, Hu YM, Wei LH, et al
    Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
    Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00435.
    PubMed     Abstract available
    
    
    
63. SCHWARTZ NG, Hernandez-Romieu AC, Annambhotla P, Filardo TD, et al
    Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report.
    Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00425.
    PubMed     Abstract available
    
    
    
64. NAZARETH J, Pan D, Martin CA, Barr I, et al
    Is the UK prepared for seasonal influenza in 2022-23 and beyond?
    Lancet Infect Dis. 2022 Aug 3. pii: S1473-3099(22)00503.
    PubMed    
    
    
    
65. BURKI T
    Guidelines for visceral leishmaniasis and HIV co-infection.
    Lancet Infect Dis. 2022;22:1124-1125.
    PubMed    
    
    
    
66. PETERS RPH, Chico RM, Rowley J, Low N, et al
    Estimating the global burden of sexually transmitted infections.
    Lancet Infect Dis. 2022;22:1112-1113.
    PubMed    
    
    
    
67. THE LANCET INFECTIOUS DISEASES
    Reaching the vulnerable without stigma.
    Lancet Infect Dis. 2022;22:1091.
    PubMed    
    
    
    
68. AYLES H, Mureithi L, Simwinga M
    The state of tuberculosis in South Africa: what does the first national tuberculosis prevalence survey teach us?
    Lancet Infect Dis. 2022;22:1094-1096.
    PubMed    
    
    
    July 2022
69. HENTZIEN M, Autran B, Piroth L, Yazdanpanah Y, et al
    A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
    Lancet Infect Dis. 2022 Jul 18. pii: S1473-3099(22)00495.
    PubMed    
    
    
    
70. CHARLES H, Prochazka M, Thorley K, Crewdson A, et al
    Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
    Lancet Infect Dis. 2022 Jul 6. pii: S1473-3099(22)00370.
    PubMed     Abstract available
    
    
    
71. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
    Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
    PubMed     Abstract available
    
    
    
72. GIROMETTI N, Byrne R, Bracchi M, Heskin J, et al
    Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis.
    Lancet Infect Dis. 2022 Jul 1. pii: S1473-3099(22)00411.
    PubMed     Abstract available
    
    
    June 2022
73. COTTON MF, Madhi SA, Luabeya AK, Tameris M, et al
    Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
    Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00222.
    PubMed     Abstract available
    
    
    
74. TEMFACK E, Lortholary O
    Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa.
    Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00315.
    PubMed    
    
    
    
75. MASHAU RC, Meiring ST, Quan VC, Nel J, et al
    Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
    Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00234.
    PubMed     Abstract available
    
    
    
76. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
    Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
    Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
    PubMed    
    
    
    May 2022
77. CANNON C, Celum C
    Sexually transmissible infection incidence in men who have sex with men using HIV pre-exposure prophylaxis in Australia.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00284.
    PubMed    
    
    
    
78. TRAEGER MW, Guy R, Asselin J, Patel P, et al
    Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
    PubMed     Abstract available
    
    
    
79. SEGERAL O, Dim B, Durier C, Nhoueng S, et al
    Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00206.
    PubMed     Abstract available
    
    
    
80. MOYO S, Ismail F, Van der Walt M, Ismail N, et al
    Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00149.
    PubMed     Abstract available
    
    
    
81. LO NC, Bezerra FSM, Colley DG, Fleming FM, et al
    Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00221.
    PubMed     Abstract available
    
    
    
82. KELLY JD, Van Ryn C, Badio M, Fayiah T, et al
    Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study.
    Lancet Infect Dis. 2022 May 16. pii: S1473-3099(22)00127.
    PubMed     Abstract available
    
    
    
83. NDJEKA N, Campbell JR, Meintjes G, Maartens G, et al
    Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2022 May 2. pii: S1473-3099(21)00811.
    PubMed     Abstract available
    
    
    April 2022
84. STEED D, Collins J, Farris AB, Guarner J, et al
    Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV.
    Lancet Infect Dis. 2022 Apr 29. pii: S1473-3099(22)00276.
    PubMed     Abstract available
    
    
    
85. YAN X, Jia Z, Zhang B
    Evaluating the risk compensation of HIV/AIDS prevention measures.
    Lancet Infect Dis. 2022;22:447-448.
    PubMed    
    
    
    March 2022
86. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
    SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
    PubMed     Abstract available
    
    
    
87. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
    Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
    PubMed     Abstract available
    
    
    
88. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
    World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
    PubMed    
    
    
    
89. MUSHTAQ A, Kazi F
    Updates in pre-exposure prophylaxis for HIV.
    Lancet Infect Dis. 2022;22:320.
    PubMed    
    
    
    
90. BAGCCHI S
    Mother-to-child transmission of HIV in Botswana.
    Lancet Infect Dis. 2022;22:319.
    PubMed    
    
    
    February 2022
91. NAIDOO K, Dookie N
    Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
    Lancet Infect Dis. 2022 Feb 25. pii: S1473-3099(21)00613.
    PubMed     Abstract available
    
    
    
92. DECROO T, van Deun A
    Implications of bedaquiline-resistant tuberculosis.
    Lancet Infect Dis. 2022;22:166-167.
    PubMed    
    
    
    January 2022
93. LANGE C, Bottger EC, Cambau E, Griffith DE, et al
    Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00586.
    PubMed     Abstract available
    
    
    
94. SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
    Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
    PubMed     Abstract available
    
    
    
95. DE VRIES HJC, de Laat M, Jongen VW, Heijman T, et al
    Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
    Lancet Infect Dis. 2022 Jan 19. pii: S1473-3099(21)00625.
    PubMed     Abstract available
    
    
    
96. KIRBY T
    Long-acting injectable for HIV approved for use in the UK.
    Lancet Infect Dis. 2022;22:26.
    PubMed    
    
    
    December 2021
97. 
    Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
    PubMed     Abstract available
    
    
    
98. SAMARASEKERA U
    Minoo Mohraz-Iran's leader in HIV research.
    Lancet Infect Dis. 2021;21:1640.
    PubMed    
    
    
    
99. KIRBY T
    Philippa Musoke-stop mother-to-child HIV transmission.
    Lancet Infect Dis. 2021;21:1641.
    PubMed    
    
    
    November 2021
100. DAWSON Q
     Is violence the only option to obtain health for HIV prisoners?
     Lancet Infect Dis. 2021 Nov 30. pii: S1473-3099(21)00757.
     PubMed    
     
     
     
101. DHANA A, Hamada Y, Kengne AP, Kerkhoff AD, et al
     Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis.
     Lancet Infect Dis. 2021 Nov 17. pii: S1473-3099(21)00387.
     PubMed     Abstract available
     
     
     
102. ISMAIL NA, Omar SV, Moultrie H, Bhyat Z, et al
     Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
     Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00470.
     PubMed     Abstract available
     
     
     
103. GOLDSTONE SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, et al
     Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
     Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00327.
     PubMed     Abstract available
     
     
     October 2021
104. KRUTIKOV M, Faust L, Nikolayevskyy V, Hamada Y, et al
     The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-gamma release assays: a systematic review and meta-analysis.
     Lancet Infect Dis. 2021 Oct 1. pii: S1473-3099(21)00261.
     PubMed     Abstract available
     
     
     September 2021
105. RULE R, Mitton B, Govender NP, Hoffmann D, et al
     Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV.
     Lancet Infect Dis. 2021 Sep 29. pii: S1473-3099(20)30979.
     PubMed     Abstract available
     
     
     
106. 
     Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.
     Lancet Infect Dis. 2021 Sep 23. pii: S1473-3099(21)00449.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.